The Influence of Hepatitis C Virus Genotype on Treatment Response to Pegylated Interferon and Ribavirin Therapy: A Review of an Established Predictive Factor

Abstract

Introduction: Chronic infection with the Hepatitis C Virus (HCV) is a leading cause of cirrhosis and liver cancer. The primary goal of antiviral treatment is to achieve a Sustained Virologic Response (SVR), which is tantamount to a cure. For a significant period, the standard of care was combination therapy with pegylated interferon alfa and ribavirin.

Literature Review: A review of the pivotal clinical literature demonstrates that the single most important baseline factor predicting the success of this therapy was the HCV genotype. Landmark, large-scale randomized trials that established pegylated interferon and ribavirin as the standard of care consistently revealed a profound difference in treatment efficacy based on viral genetics. Patients infected with HCV genotypes 2 or 3 consistently achieved high SVR rates, typically around 80%. In stark contrast, patients with genotype 1, the most common type in many parts of the world, had much lower success rates, generally between 40-50%. This critical insight led directly to the development of genotype-specific treatment algorithms, establishing a longer, 48-week course of therapy for genotype 1 and a shorter, 24-week course for genotypes 2 and 3, optimizing the balance between efficacy and treatment-related toxicity.

Conclusion: The body of evidence firmly established HCV genotype as the cornerstone for predicting outcomes and guiding the management of interferon-based therapy. This principle of tailoring treatment duration based on viral genotype was fundamental to HCV care and essential for counseling patients on their likelihood of achieving a cure.